Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 16

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 16
---
 net proceeds we receive    
 from this Primary Offering as follows: (i) up to 80% from the net proceeds of this Offering or $3.52 million will be used for the       
 development of our product candidates and conducting the clinical trials; (ii) up to 20% from the net proceeds of this Offering or      
 $880,000 up to a million to explore and develop additional new indications beyond our current pipeline. The actual allocation of        
 net proceeds may vary depending on several factors, including the progress of clinical trials, regulatory developments, and evolving    
 strategic priorities. Until fully deployed, we may invest the net proceeds in short-term interest-bearing instruments or use them       
 for general working capital purposes.                                                                                                   |
| Risk                                                                                                                             
 Factors                                                                                                                          |     | See the discussion under                                                                                                                
 the caption “Risk Factors” and other information in this Prospectus for a discussion of factors you should                              
 carefully consider before deciding to invest in our Common Stock.                                                                       |

| (1) | As                 
 of August 13, 2025 |

| (2) | The                                                                                        
 number of shares of our Common Stock that will be outstanding after this Offering is based 
 on 60,729,100 shares of our Common Stock outstanding as of August 13, 2025 and excludes:   |

| ● | 5,200,000                                                                                                                            
 shares of Common stock issuable upon the exercise of outstanding stock options as of August 12, 2025, granted pursuant to our Global 
 Share Incentive Plan (2021), as amended (the “2021 Plan”), at a weighted-average exercise price of $0.31 per share and               |

| ● | 2,000,000                                                                                                                        
 shares of Common Stock reserved, in the aggregate, for future issuance under our 2021 Plan, as amended, as of February 14, 2025. |

| ● | 6,372,265 Common Stock                                                                                                                
 issuable upon the exercise of our outstanding warrants with the average exercise price of $1.16 per share, exercisable until December 
 31, 2026;                                                                                                                             |

Except as otherwise indicated, all information in this Prospectus:

<div align='center'>4

RISK FACTORS</div>

Investing in our Common Stock involves a high degree of risk. Before investing in our Common Stock, you should carefully consider the risks described below, as well as the other information in this Prospectus, including our consolidated financial statements and the related notes.